Condiciones de salud que DHA (ácido docosahexaenoico) puede ayudar a apoyar.
DHA, a long-chain omega-3 fatty acid present in fish oil supplements studied for acne, contributes to the anti-inflammatory effects of omega-3 fatty acid supplementation shown to have fair-quality clinical evidence for acne in a 42-study systematic review covering 3,346 participants. It modulates inflammatory cytokine production and IGF-1-driven sebocyte lipogenesis.
Observational studies associate lower circulating DHA with higher rates of anxiety disorders, and mechanistic evidence points to DHA's role in neuronal membrane function, neurotransmission, and neuroinflammation. A meta-analysis of omega-3 RCTs identified anxiolytic potential for EPA and DHA combined. Evidence is strongest for EPA-dominant formulations, and DHA-specific anxiolytic effects in RCTs remain modest and preliminary.
DHA is an omega-3 fatty acid integral to endothelial cell membrane composition that improves vascular reactivity and reduces inflammation. Clinical trials show it lowers triglycerides, improves flow-mediated dilation, reduces arterial stiffness, and has anti-atherogenic effects. Endorsed by the American Heart Association as part of omega-3 supplementation for cardiovascular risk reduction.
DHA (docosahexaenoic acid) is a long-chain omega-3 fatty acid that reduces joint inflammation by modulating arachidonic acid metabolism and generating pro-resolving lipid mediators (resolvins, protectins). Meta-analyses of fish oil (EPA+DHA) in rheumatoid arthritis confirm reductions in joint pain, stiffness, and NSAID use. DHA also supports cartilage chondrocyte health.
DHA, along with EPA, reduces arachidonic acid-derived pro-inflammatory mediators relevant to asthma and promotes synthesis of anti-inflammatory resolvins and protectins. Epidemiological evidence links higher DHA intake to reduced asthma risk. Pregnancy supplementation with DHA has been studied for reducing childhood asthma onset.
DHA is a structural omega-3 fatty acid critical to brain cell membrane composition, and children with ADHD consistently show lower DHA levels than controls. Multiple meta-analyses of RCTs indicate modest but significant improvement in ADHD symptoms—particularly inattention—with omega-3 supplementation containing DHA and EPA; higher EPA content appears to drive most benefit.
DHA, a key long-chain omega-3 fatty acid, contributes to anti-inflammatory and immunomodulatory effects in autoimmune diseases alongside EPA. It generates anti-inflammatory resolvins and protectins, and clinical trials in RA and SLE demonstrate benefits. DHA also has evidence for reducing autoimmune flare in animal models.
DHA (docosahexaenoic acid), a long-chain omega-3 fatty acid, contributes to LBP reduction as part of fish oil supplementation in multiple RCTs. DHA serves as a precursor to D-series resolvins that resolve inflammation and is involved in attenuating IVD degeneration. An RCT of 36 women supplemented with fish oil (550 mg EPA + 205 mg DHA daily for 3 months) found marked reductions in low back pain.
DHA is an omega-3 fatty acid with documented antiplatelet properties; it dose-dependently inhibits platelet aggregation and reduces integrin αIIbβ3 expression on platelet membranes. It is incorporated into platelet phospholipids where it alters membrane fluidity and reduces platelet activation responses. Evidence comes from in vitro studies, RCTs of combined EPA/DHA, and systematic reviews.
DHA, the longest-chain marine omega-3 fatty acid, contributes significantly to the antihypertensive effects of fish oil. It improves endothelial function, reduces vascular resistance, and lowers blood pressure. Both standalone DHA and DHA+EPA meta-analyses confirm significant SBP and DBP reductions.
DHA is a long-chain omega-3 fatty acid constituting approximately 97% of the omega-3 fatty acids in the brain and a major component of neuronal cell membranes. A 6-month double-blind RCT in 176 adults with low omega-3 intake found 1.16 g/day DHA significantly improved episodic and working memory versus placebo. Low DHA is associated with cognitive impairment, neuroinflammation, and brain fog.
DHA is a critical nutrient during lactation, actively secreted into breast milk and essential for infant neurological and visual development. Maternal DHA supplementation during lactation reliably increases breast milk DHA concentrations and improves infant DHA status. The American Academy of Pediatrics recommends at least 200 mg DHA/day for lactating women.
DHA deficiency is documented in celiac disease due to fat malabsorption. A 2026 University of Chile clinical trial (NCT07585669) specifically uses 2,000 mg DHA/day (plus 400 mg EPA) in newly diagnosed CeD patients alongside GFD to evaluate reduction of intestinal and systemic inflammation. DHA's anti-inflammatory mechanisms are directly relevant to CeD intestinal pathology.
DHA-containing omega-3 formulations are FDA-approved for treating severe hypertriglyceridemia and reliably reduce triglycerides by 20–30% at pharmacological doses (3.4–4 g/day). DHA-containing preparations may modestly raise LDL cholesterol, unlike EPA-only formulations, but do not increase non-HDL cholesterol. HDL cholesterol shows slight increases in some studies.
DHA (docosahexaenoic acid) has substantial human clinical and mechanistic evidence supporting its role in reducing chronic inflammation. It acts through multiple pathways, including inhibition of NF-κB, suppression of pro-inflammatory cytokines, and generation of specialized pro-resolving mediators (SPMs) such as resolvins and protectins. Meta-analyses of randomized controlled trials demonstrate reductions in CRP, particularly in populations with elevated baseline inflammation such as cardiometabolic disorders. Effects are most pronounced at intakes generally above 1–2 g/day of combined EPA+DHA.
DHA is the principal structural omega-3 fatty acid in neural membranes and a precursor to D-series resolvins and protectins that resolve neuroinflammation. Combined EPA+DHA supplementation is supported by systematic review evidence for chronic pain reduction (SMD −0.55). DHA modulates inflammatory signaling relevant to neuropathic and musculoskeletal chronic pain.
DHA is a long-chain omega-3 fatty acid integral to endothelial cell membrane fluidity, NO-dependent vasodilation, and anti-inflammatory signalling. Meta-analyses of combined DHA/EPA supplementation consistently demonstrate blood pressure reductions and improved arterial compliance. DHA specifically improves red blood cell deformability, reduces blood viscosity, and exerts vasodilatory effects via enhanced endothelial NO production.
DHA is the principal omega-3 fatty acid concentrated in the brain and is supported by multiple human clinical trials and systematic reviews for its role in cognitive aging. Evidence is strongest for early-stage cognitive decline and age-related cognitive decline, while benefits in established Alzheimer's disease are not demonstrated. Observational data consistently link higher DHA levels with reduced dementia risk, though RCT results remain mixed depending on disease stage and population.
DHA is the predominant omega-3 fatty acid in the brain and is depleted following traumatic brain injury. A pilot RCT in adolescent athletes found 2 g/day of DHA for 12 weeks shortened symptom resolution by ~4 days and return-to-play by ~5 days versus placebo. Preclinical studies consistently show DHA reduces axonal damage, neuroinflammation, oxidative stress, and neuronal death after mTBI. A 2024 U.S. Military information paper and a 2014 peer-reviewed review both identified DHA as the most evidence-supported nutritional intervention for concussion recovery.
DHA is an omega-3 fatty acid showing particularly strong associations with lung function preservation in COPD. A large longitudinal study (n>15,000) found that higher DHA concentrations were specifically associated with improved lung capacity over time. DHA is metabolized to protectins and resolvins that help resolve airway inflammation.
DHA is a major omega-3 component of fish oil studied alongside EPA for Crohn's disease. It serves as a precursor to pro-resolving mediators (resolvins, protectins). RCT evidence (EPIC trials, JAMA 2008) found no significant benefit for remission maintenance, though DHA bioavailability in CD patients is documented in a crossover RCT.
DHA is a long-chain omega-3 fatty acid involved in neuronal membrane structure and neurotransmitter function. It contributes to antidepressant effects as part of omega-3 preparations, though EPA-predominant formulations generally show stronger effects. DHA supplementation has been shown to elevate red-cell membrane levels correlating with attenuation of depressive symptoms in clinical studies.
DHA (from fish oil) has been studied as part of omega-3 supplementation in atopic dermatitis. Anti-inflammatory mechanisms via prostaglandin/leukotriene modulation are well-established. Clinical evidence when studied as part of fish oil in AD is inconsistent per AAD/NCCIH guidelines, though biological rationale is robust.
DHA is co-recommended alongside EPA by authoritative diverticular disease protocols as an anti-inflammatory omega-3 fatty acid. Fish oil containing both EPA and DHA is specifically recommended by multiple evidence-based diverticulitis management resources at 1,000–2,000 mg/day to address the inflammatory component of diverticular disease.
DHA is the other principal long-chain omega-3 fatty acid co-evaluated with EPA in dry eye RCTs. It is incorporated into lacrimal gland cell membrane phospholipids, modulating inflammatory signaling. Clinical meta-analyses confirm combined EPA+DHA supplements improve TBUT, Schirmer test, and OSDI scores in DED patients.
DHA is a long-chain omega-3 PUFA from fish and microalgae that integrates into skin cell membranes, improving membrane fluidity and barrier function and reducing TEWL. Systematic reviews and clinical studies confirm DHA-containing preparations improve dry skin and enhance barrier integrity. Together with EPA, DHA reduces pro-inflammatory mediators that compromise skin barrier hydration.
DHA is a long-chain omega-3 fatty acid studied as a dietary supplement in atopic eczema. A specific RCT comparing DHA versus saturated fatty acid controls in eczema patients found benefit, and DHA was included as a standalone evaluated intervention in the Cochrane dietary supplement review for established atopic dermatitis.
DHA, the primary omega-3 fatty acid of brain tissue, exerts anti-epileptic effects by increasing seizure latency in PTZ models and elevating cortical seizure thresholds. In a comparative clinical trial, epileptic patients receiving DHA (417 mg/day) had significantly fewer monthly seizures (11.9) than placebo (16.6). A 2025 meta-analysis of RCTs confirms omega-3/DHA supplementation reduces seizures in adults with drug-resistant epilepsy.
DHA is a structural omega-3 fatty acid found in high concentrations in the retina and is essential for maintaining photoreceptor cell membrane integrity. It has anti-inflammatory properties relevant to the ocular surface dysfunction underlying digital eye strain and dry eye. A 2023 systematic review and meta-analysis (19 RCTs, 4,246 patients) found omega-3 supplementation (EPA+DHA) significantly improved tear film stability and dry eye symptom scores.
DHA is the most abundant omega-3 in sperm plasma membranes and is specifically essential for flagellar motility, capacitation, and the acrosome reaction. Low testicular and seminal DHA is a recognized marker of asthenozoospermia. An RCT of 238 infertile men found DHA 1.84 g/day for 32 weeks significantly improved sperm motility, concentration, and morphology vs. placebo.
DHA is a key omega-3 fatty acid found in follicular fluid and oocyte membranes; higher follicular DHA correlates with improved oocyte and embryo quality. Studies in ART populations show DHA supplementation supports oocyte maturation and embryo development, and it is a standard component of fertility-oriented omega-3 supplements.
DHA is the principal structural omega-3 fatty acid in the brain, and children with ADHD have significantly lower DHA blood levels than controls (meta-analysis, Hedges' g = -0.76). RCTs show DHA supplementation combined with EPA improves parent-rated attention in children with and without ADHD. DHA is also critical for normal brain development throughout childhood and adolescence.
DHA is the predominant omega-3 fatty acid in brain gray matter and is essential for neuronal membrane fluidity and neurotransmitter receptor function. RCTs support improvements in memory and attention in older adults with age-related memory concerns and in children. The FDA has recognized DHA as important for brain health, and the NIH ODS acknowledges omega-3 fatty acids' role in cognitive function.
DHA is an omega-3 fatty acid that directly inhibits IgE production by human B cells via STAT6 and NF-κB pathway interference. Mendelian randomization studies found direct causal association between DHA levels and reduced atopic dermatitis risk. DHA and EPA in vitro demonstrated decreased IgE-pathway signaling in allergy models, supporting its use for food sensitization prevention.
DHA is the predominant omega-3 fatty acid in photoreceptor outer segment membranes, comprising approximately 50–60% of total fatty acids in rod outer segments. It is essential for photoreceptor membrane fluidity, rhodopsin function, retinal development, and neuroprotection. Clinical evidence supports its role in dry eye disease management and retinal integrity.
DHA is the predominant omega-3 fatty acid in retinal ganglion cells and photoreceptor membranes. It reduces oxidative damage, improves ocular blood flow, and is neuroprotective in glaucoma models. A 2018 systematic review identified DHA/omega-3 fatty acids among key nutrients with putative protective effects in glaucoma.
DHA is an omega-3 fatty acid evaluated alongside EPA in multiple RCTs for periodontal disease. Combined EPA+DHA supplementation as adjunct to SRP has been shown in RCTs and a meta-analysis to improve probing pocket depth, clinical attachment level, and gingival inflammation in periodontitis patients. DHA generates D-series resolvins and protectins that actively promote periodontal tissue healing.
DHA is a long-chain omega-3 PUFA with well-established gut-brain axis activity. It modulates gut microbiota composition by promoting Bifidobacterium and Lactobacillus populations, maintains gut and blood-brain barrier integrity, supports neurogenesis and synaptic plasticity, and reduces neuroinflammation. Clinical evidence links DHA deficiency to depression and cognitive impairment.
DHA, a long-chain omega-3 fatty acid found in fish oil, contributes to migraine prophylaxis through anti-inflammatory and neuroprotective mechanisms. Network meta-analyses and RCTs support EPA/DHA combinations for reducing migraine frequency, with high-dose supplementation showing the strongest evidence.
DHA is the principal structural omega-3 fatty acid of the brain and retina, declining in neural tissue with age. Clinical evidence shows DHA slows cognitive aging, improves memory in older adults with mild cognitive impairment, protects against telomere shortening, and reduces neuroinflammation. The VITAL trial and multiple RCTs support DHA supplementation for healthy aging.
DHA is a long-chain omega-3 fatty acid that is highly concentrated in neural tissues and is essential for brain and retinal development in infants and children. A systematic review and meta-analysis (Frontiers in Neurology, 2024) confirmed that DHA supplementation during pregnancy and lactation, and DHA fortification of infant formula, leads to increased DHA in infant tissues and improved neurological and visual development. It accumulates in the fetal brain during gestation and continues accumulating through the first year of life.
DHA constitutes over 50% of the fatty acids in retinal photoreceptor cell outer segments, making it structurally critical for retinal function. It was evaluated in the AREDS2 trial (350 mg/day with 650 mg EPA) for AMD protection, and observational AREDS data found high omega-3 intake associated with 30% lower risk of geographic atrophy and neovascular AMD. It has established anti-inflammatory roles in retinal aging.
Clinical evidence for DHA and omega-3 fatty acids in body weight reduction is mixed; most RCTs show no significant effect on body weight alone, but some data support modest reductions in waist circumference. Effects appear most meaningful when omega-3 supplementation is combined with caloric restriction, and triglyceride-lowering effects are well-established even when weight effects are absent.
DHA (docosahexaenoic acid), a marine-derived omega-3 fatty acid, has robust clinical and epidemiological evidence supporting its role in cardiovascular health. It lowers triglycerides, reduces blood pressure, improves vascular function, and is associated with reduced risk of cardiovascular events and mortality. Evidence from meta-analyses of randomized controlled trials and cohort studies consistently links higher DHA intake or circulating levels to improved cardiac outcomes, though DHA's independent effect versus EPA remains an area of active investigation.
DHA (docosahexaenoic acid) is an omega-3 fatty acid that has been shown to participate in homocysteine metabolism via phosphatidylcholine pathways and the PEMT enzyme. Meta-analyses of RCTs show omega-3 supplementation including DHA significantly reduces plasma homocysteine. DHA's interaction with homocysteine is clinically relevant to cognitive outcomes, particularly in older adults.
DHA is a long-chain omega-3 fatty acid concentrated in brain and adrenal tissue with evidence for modulating HPA axis stress reactivity. A 2025 American Journal of Medicine review recommends combined EPA+DHA (1.25–3.0 g/day) for cortisol reduction and stress resilience improvement. NIH documents confirm DHA decreases the magnitude of HPA axis response to stressors.
DHA is an omega-3 fatty acid from marine sources studied in combination with EPA for IBD management. Clinical evidence shows combined EPA/DHA reduces CD relapse. DHA alone showed protective associations with Crohn's disease in longitudinal cohort data.
DHA (docosahexaenoic acid) is an omega-3 PUFA with documented association with improved intestinal barrier integrity. In the LIBRE randomized controlled trial (PMC10468946), plasma DHA was inversely associated with fecal zonulin (a marker of intestinal permeability) in both bivariate and multivariate analyses. DHA also plays a role in maintaining and protecting tight junction structure and function as documented in intestinal epithelial cell studies.
DHA is the dominant omega-3 fatty acid in the brain (~40% of total fatty acids in neurons) and is essential for neuronal membrane integrity, synaptic plasticity, and neurotransmitter signaling. Multiple meta-analyses of RCTs show that DHA supplementation improves memory function and cognitive performance, particularly in individuals with MCI or insufficient dietary omega-3 intake.
DHA is the most abundant polyunsaturated fatty acid in photoreceptor outer segment membranes and plays structural and anti-inflammatory roles in the retina. Multiple large epidemiological studies and meta-analyses link higher DHA intake to significantly reduced AMD risk, with one 2025 meta-analysis (18 studies) finding an 18% pooled reduction in AMD odds with higher omega-3 intake. A UK Biobank prospective cohort (n=258,350) found each mmol/L rise in plasma DHA reduced AMD risk by 35%.
DHA is the predominant omega-3 fatty acid in brain gray matter and is essential for neuronal membrane fluidity, synaptic function, and neuroprotection. Multiple RCTs show DHA supplementation can improve memory outcomes, particularly in older adults with age-related cognitive decline or low DHA status. Expert reviews identify omega-3 DHA as having among the strongest randomized evidence for memory support.
DHA is an essential omega-3 fatty acid supporting cardiovascular and cognitive health during menopause. The cognitive decline and mood disturbances associated with menopause may be partially addressable with DHA supplementation. Combined with EPA, DHA-containing omega-3 supplements are supported for postmenopausal cardiovascular protection per multiple systematic reviews.
DHA is the predominant omega-3 fatty acid in the brain, integral to synaptic membrane composition, neurotransmission, neurogenesis, and cognitive function across the lifespan. Clinical RCTs show improvements in specific memory domains and learning in adults with age-related cognitive decline, though results in healthy adults and those with more advanced dementia are less consistent.
DHA (docosahexaenoic acid), a marine-derived long-chain omega-3 fatty acid, has well-documented clinical evidence supporting its role in addressing key components of metabolic syndrome, most robustly hypertriglyceridemia. Multiple systematic reviews and meta-analyses of RCTs confirm significant triglyceride-lowering effects, with more modest or inconsistent effects on blood pressure, insulin resistance, and other MetS markers. The evidence base is clinical and mechanistic, not traditional.
DHA is a long-chain omega-3 fatty acid that contributes to reducing exercise-induced muscle damage and soreness by enhancing membrane fluidity and reducing inflammatory signaling. Meta-analyses confirm omega-3 supplements (DHA as key component) reduce CK, LDH, and myoglobin post-exercise.
DHA, a long-chain omega-3 fatty acid, contributes to anti-inflammatory and pro-resolving pathways in muscle tissue. Combined EPA+DHA supplementation has been studied in multiple RCTs and reviews for DOMS and musculoskeletal pain, with consistent anti-inflammatory effects at doses of 2–3 g/day EPA+DHA.
DHA is a long-chain omega-3 fatty acid that is the dominant structural lipid in the brain and retina, essential for neuronal membrane fluidity, neurotransmitter release, and nervous system development. Deficiency is linked to impaired cognition, learning, and behavior across the lifespan.
Docosahexaenoic acid (DHA) is the principal omega-3 fatty acid incorporated into neuronal membrane phospholipids and is critical for neuronal membrane integrity and signal transduction. Preclinical studies confirm DHA-containing omega-3 sources improve nerve conduction velocity, intraepidermal nerve density, and corneal nerve fiber length in diabetic neuropathy models. Combined with curcumin, DHA demonstrated spinal cord neuroprotection with BDNF elevation in a myelopathy model.
DHA is the dominant omega-3 fatty acid in neuronal membranes and is essential for neurite outgrowth, synaptogenesis, and BDNF-mediated neuronal survival. A 2023 meta-analysis of controlled trials found omega-3 supplementation significantly raised serum BDNF levels (pooled WMD +1.01 μmol/L, p=0.003). DHA deficiency impairs neuroplasticity gene expression in animals.
DHA is the predominant omega-3 in brain membranes, comprising ~40% of neuronal PUFAs and maintaining serotonin and dopamine receptor membrane environment. Deficiency reduces serotonin release and dopamine function. It is essential for normal neurotransmitter signal transduction and brain neurotransmitter development from infancy through adulthood.
DHA is the dominant structural fatty acid in photoreceptor outer segment membranes, comprising over 50% of phospholipid acyl chains in rods and cones where phototransduction occurs. DHA is required for photoreceptor membrane biogenesis, fluidity, and rhodopsin function. DHA deficiency impairs retinal function and visual acuity in animal models and human infants.
DHA is a long-chain n-3 PUFA that reduces pro-inflammatory bone-resorbing cytokines and supports osteoblast function. Preclinical evidence and epidemiological data link higher DHA intake to better bone density and reduced osteoporosis risk. Combined with EPA in fish oil studies, DHA-containing supplementation has shown improvements in bone formation markers in clinical trials.
DHA, a long-chain omega-3 fatty acid, has been shown in a rat cerulein model to inhibit NF-κB and PKCδ activation, reduce IL-6 expression, and limit oxidative damage in the pancreas, suggesting potential to prevent or ameliorate pancreatitis. Omega-3 fatty acid supplementation including DHA has been studied in clinical nutrition trials in acute pancreatitis.
DHA, the primary omega-3 fatty acid in brain tissue, has been studied in Parkinson's disease for its neuroprotective and anti-neuroinflammatory properties. Small clinical studies suggest omega-3 supplementation (including DHA) may modestly improve UPDRS scores in PD patients. Epidemiological data link higher fish oil/omega-3 intake with reduced PD risk.
DHA is a key long-chain omega-3 fatty acid with evidence for cognitive support, mood regulation, and anti-inflammatory activity during perimenopause. It is specifically noted in perimenopausal contexts for brain fog and mood, and is included in algae-based formulations recommended for perimenopausal women.
DHA is a critical omega-3 fatty acid for brain and eye development that is found almost exclusively in fatty fish and seafood—foods commonly refused by picky eaters. Pediatric nutrition authorities recommend DHA supplementation for children with limited fish intake. It is explicitly listed among top picky eater nutrient gaps.
The principal structural omega-3 fatty acid of neuronal membranes, DHA has documented anti-inflammatory and neuroprotective properties supporting post-illness recovery—particularly neurological and cognitive recovery. Post-traumatic recovery protocols and COVID-19 recovery literature specifically cite DHA as a priority nutrient.
DHA is an omega-3 fatty acid that reduces post-surgical inflammation and supports tissue recovery. A 2025 meta-analysis of 34 RCTs (n=2889) found omega-3 PUFA supplementation (including DHA) significantly reduced inflammatory markers, hospital stay, and infectious complications after colorectal cancer surgery. DHA also supports neurological recovery after surgical trauma to neural tissue.
DHA is an omega-3 fatty acid essential for neurological recovery and inflammation resolution, serving as the precursor to D-series resolvins, protectins, and maresins. It is specifically included in the VA Long COVID protocol for post-viral recovery and is documented to support cognitive function and neurological recovery—targeting post-viral brain fog and neurological sequelae.
DHA is an omega-3 fatty acid selectively transferred from maternal to fetal/infant tissue; pregnancy and lactation deplete maternal DHA by up to 50%, and low DHA is associated with postpartum depression risk. A 2025 PMC systematic review confirmed marine-origin DHA ≥200 mg/day is a core postpartum supplement. Most clinical authorities including WHO and NIH list DHA as a priority nutrient for postpartum and breastfeeding women.
DHA is the primary structural omega-3 fatty acid in fetal brain and retinal membranes, critical during third-trimester brain growth. The NIH ODS and ACOG list omega-3 fatty acids/DHA among nutrients underconsumed during pregnancy. A Cochrane meta-analysis of 70 RCTs (19,927 participants) found omega-3 (mainly DHA) supplementation reduced preterm births before 34 weeks by 42%. ACOG and Dietary Guidelines for Americans recommend 250–375 mg EPA+DHA/day for pregnant women.
Omega-3 fatty acids including DHA have been studied as adjunctive therapy in psoriasis, with evidence suggesting reduction in erythema, itching, and scaling through suppression of leukotriene B4 and pro-inflammatory cytokines. Clinical trial results are mixed, with some showing improvement in PASI scores and dermatological quality-of-life indices, while at least one large double-blind trial failed to show clinical benefit despite favorable biochemical changes.
DHA is co-administered with EPA in fish oil RCTs for Raynaud's. Combined EPA (3.96 g) plus DHA (2.64 g) daily for 17 weeks significantly reduced cold-induced vasospastic reactions in primary Raynaud's. DHA contributes antiplatelet and anti-inflammatory effects complementary to EPA. Life Extension's Raynaud's protocol and authoritative reviews list EPA and DHA together as supported interventions for primary Raynaud's.
DHA is an omega-3 fatty acid that, along with EPA, forms the anti-inflammatory basis of fish oil therapy in RA. It reduces prostaglandin and leukotriene synthesis, modulates immune cell function, and generates anti-inflammatory resolvins D. Combined EPA+DHA supplementation significantly reduces RA clinical activity in multiple RCTs.
DHA is an omega-3 fatty acid reviewed alongside EPA in the Archives of Dermatological Research 2024 systematic analysis (PMC11065919) of rosacea vitamins and nutrients. Combined EPA+DHA significantly improved ocular rosacea (xerophthalmia) in a clinical study (64% of patients). DHA reduces systemic inflammation via D-series resolvins and supports meibomian gland lipid quality.
DHA is the primary structural omega-3 fatty acid in neuronal membranes and is specifically reported to be reduced in patients with seasonal winter affective disorder alongside EPA. While EPA drives more of the acute antidepressant effect in RCTs, DHA supports neuronal membrane fluidity, serotonin receptor density, and brain health relevant to seasonal mood. It is co-identified in studies documenting omega-3 deficits in SAD populations.
A cross-sectional study in 350 patients undergoing sleep studies (Journal of Clinical Sleep Medicine) found that red blood cell DHA levels were inversely related to OSA severity; each 1-SD increase in DHA was associated with approximately 50% lower odds of severe OSA after controlling for confounders. Low DHA is biologically plausible in OSA through its role in neuronal membrane function and anti-inflammatory pathways.
DHA (docosahexaenoic acid) is a marine omega-3 fatty acid with well-established triglyceride-lowering effects. Combined with EPA, DHA at doses of 2–4 g/day produces clinically meaningful TG reductions in both hypertriglyceridemic and diabetic patients. It is a primary component of FDA-approved prescription omega-3 drugs.
Volver